3 recruiting, 2 completed, 2 not yet recruiting, 2 terminated. 4 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Completed 1, Recruiting 1 |
| Not applicable | 2 | Recruiting 1, Suspended 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow TerSera Therapeutics LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer ZOLADEX - Advanced Breast Cancer, Early Breast Cancer | Phase 1 | Recruiting | TerSera Therapeutics LLC | 176 | 2026-10-30 | 2026-10-13 |
| Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT) - Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy) | Not applicable | Recruiting | CHU de Quebec-Universite Laval | 434 | 2026-05-13 | 2026-07-01 |
| Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy Ziconotide - Chemotherapy Induced Peripheral Neuropathy (CIPN) | Not yet recruiting | Christian Hospital Northeast Northwest | 24 | 2026-05-02 | 2026-03-30 | |
| PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer SBRT combined with ADT - Prostate Cancer (Adenocarcinoma), Erectile Abnormalities | Not yet recruiting | CancerCare Manitoba | 130 | 2026-03-16 | 2026-03-10 | |
| Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer Radiotherapy - Prostate Metastases | Phase 2 | Recruiting | University Health Network, Toronto | 40 | 2023-08-09 | 2026-03-23 |
| Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. Report and compare changes in a non-inferiority analysis of the International Prostate Symptom Score (I-PSS), Report and compare changes in a non-inferiority analysis of the expanded prostate cancer index composite" (EPIC-26):, Report and compare changes in a non-inferiority analysis of the Sexual Health Inventory for Men (SHIM) - Prostate Cancer, Node; Prostate | Not applicable | Suspended | CHU de Quebec-Universite Laval | 500 | 2022-09-01 | 2025-09-12 |
| Telotristat With Lutathera in Neuroendocrine Tumors Telotristat (Low-Dose), Telotristat (High-Dose) - Neuroendocrine Tumors | Phase 2 | Terminated | Lowell Anthony, MD | 1 | 2021-09-13 | 2023-06-27 |
| Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel - Oncology Patients Receiving Chemotherapy | Phase 2 | Completed | TerSera Therapeutics LLC | 34 | 2020-03-25 | 2023-10-06 |
| A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer telotristat ethyl - Biliary Tract Cancer (BTC) | Phase 2 | Terminated | TerSera Therapeutics LLC | 53 | 2019-03-13 | 2023-04-19 |
| Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO Xermelo - Carcinoid Syndrome | Completed | TerSera Therapeutics LLC | 223 | 2017-06-22 | 2024-07-24 | |
| Margetuximab Expanded Access Program Margetuximab - HER2-positive Breast Cancer, HER2-positive Carcinoma | Approved for marketing | TerSera Therapeutics LLC | 2025-02-14 |
Prostatic Neoplasms (3) · Neuroendocrine Tumors (2) · Radiation Injuries (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Chronic Pain (1) · Erectile Dysfunction (1) · Gastrointestinal Diseases (1) · Neoplasm Recurrence, Local (1) · Serotonin Syndrome (1) · Urologic Diseases (1)
telotristat ethyl (3) · Androgen Antagonists (2) · Cetirizine (1) · Cisplatin (1) · Diphenhydramine (1) · Goserelin (1) · Menogaril (1) · Paclitaxel (1) · Radiotherapy (1) · Rituximab (1) · cytokine inducible SH2-containing protein (1) · ibritumomab tiuxetan (1) · margetuximab (1) · obinutuzumab (1) · ocrelizumab (1)
United States (6) · Canada (4)
Andre-Guy Martin, MD MSc FRCPC (1) · Christine Fredericks (1) · Christopher L Beuer, MD (1) · Eric Vigneault, MD, MSc (1) · Janine North, B.S. (1) · Janine North, BS (1) · Lowell Anthony, MD (1) · Renuka Iyer, M.D. (1) · Richard Kim, M.D. (1)